Court ruling in favour of TyraTech

TYRATECH, INC.

("TyraTech" or the "Company")

Court ruling in favour of TyraTech

26 October 2011

TyraTech, Inc. (AIM: TYR), a natural life sciences company, is pleased to announce that the State of New York Court of Appeals (the highest court in New York) issued a decision on 20 October 2011 denying Molecular Securities, Inc.'s ("Molecular") request to appeal the 26 May 2011 ruling by the New York Supreme Court, Appellate Division of New York County, in favour of TyraTech and against Molecular which dismissed Molecular's complaint in its entirety. As a result, no further appeals by Molecular are available in New York State.

In November of 2008, Molecular filed a Complaint against the Company asserting claims for breach of contract and quantum merit. Molecular alleged that it was owed US$2,760,470 for services it allegedly provided to TyraTech plus interest, attorneys' fees and costs.

The Company believes the Court of Appeals ruling will bring to an end any further litigation against TyraTech in a case which the Company strongly defended itself whilst refuting all claims throughout the process.

For further information please contact:

TyraTech Inc.

Alan Reade, Executive Chairman

Tel: +1 919 415 4310

Peter Jerome, Chief Financial Officer

Tel: +1 919 415 4280

Brewin Dolphin Limited, Nominated Advisor

Robert Beenstock

Tel: +44 207 248 4400